Efficacy and tolerability of eplerenone and losartan in hypertensive of eplerenone and black and white patients

被引:173
作者
Flack, JM [1 ]
Oparil, S
Pratt, JH
Roniker, B
Garthwaite, S
Kleiman, JH
Yang, YH
Krause, SL
Workman, D
Saunders, E
机构
[1] Wayne State Univ, Dept Internal Med, Detroit, MI 48202 USA
[2] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA
[3] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA
[4] Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA
[5] Pharmacia Corp, Cardiovasc Metab Dis, Skokie, IL USA
[6] Univ Maryland, Div Hypertens, Baltimore, MD 21201 USA
关键词
D O I
10.1016/S0735-1097(03)00054-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The purpose of this study was to evaluate the efficacy and tolerability of monotherapy with the selective aldosterone blocker eplerenone in both black and white patients with hypertension. BACKGROUND Essential hypertension and cardiovascular-renal-target organ damage is more prevalent in black than white adults in the U.S. METHODS Black (n = 348) and white (n = 203) patients with mild-to-moderate hypertension were randomized to double-blind treatment with eplerenone 50 mg, the angiotensin Il receptor antagonist losartan 50 mg, or placebo once,daily. Doses were increased if blood pressure remained uncontrolled. The primary end point was change in mean diastolic blood pressure (DBP) after 16 weeks of therapy. RESULTS Adjusted mean changes from baseline in DBP were -5.3 +/- 0.7, -10.3 +/- 0.7, and -6.9 +/- 0.6 mm Hg in the placebo, eplerenone-treated, and losartan-treated groups, respectively (mean SE, p < 0.001 eplerenone vs. placebo, p < 0.001 eplerenone vs. losartan). In black patients, DBP decreased by -4.8 +/- 1.0, -10.2 +/- 0.9, and -6.0 +/- 0.9 mm Hg for the placebo, eplerenone-treated, and losartan-treated groups, respectively (mean +/- SE, p < 0.001 eplerenone vs. placebo, p < 0.001 eplerenone vs. losartan), whereas in white patients, DBP decreased by -6.4 +/- 1.0, -11.1 +/- 1.1, and -8.4 +/- 1- 1.0 mm Hg, respectively (p 0.001 eplerenone vs. placebo, p = 0.068 for eplerenone vs. losartan). For reduction of systolic blood pressure (SBP), eplerenone was superior to placebo and losartan in all patients combined and in black patients, and was superior to placebo in white patients. Eplerenone was as effective as losartan in reducing SBP and DBP in the high renin patient, but more effective than losartan in the low renin patient. Similarly, eplerenone was at least as effective as losartan in patients with differing baseline levels of aldosterone. Both eplerenone and losartan were well tolerated. CONCLUSIONS The antihypertensive effect of eplerenone was equal in black and white patients and was superior to losartan in black patients.
引用
收藏
页码:1148 / 1155
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[2]   PREVALENCE OF HYPERTENSION IN THE US ADULT-POPULATION - RESULTS FROM THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY, 1988-1991 [J].
BURT, VL ;
WHELTON, P ;
ROCCELLA, EJ ;
BROWN, C ;
CUTLER, JA ;
HIGGINS, M ;
HORAN, MJ ;
LABARTHE, D .
HYPERTENSION, 1995, 25 (03) :305-313
[3]   CONTROL OF BLOOD-PRESSURE AND END-ORGAN DAMAGE IN MATURING SALT-LOADED STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS BY ORAL ANGIOTENSIN-II RECEPTOR BLOCKADE [J].
CAMARGO, MJF ;
VONLUTTEROTTI, N ;
CAMPBELL, WG ;
PECKER, MS ;
JAMES, GD ;
TIMMERMANS, PB ;
LARAGH, JH .
JOURNAL OF HYPERTENSION, 1993, 11 (01) :31-40
[4]   Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States [J].
Cushman, WC ;
Reda, DJ ;
Perry, HM ;
Williams, D ;
Abdellatif, M ;
Materson, BJ .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (06) :825-831
[5]   ANTIALDOSTERONES - INCIDENCE AND PREVENTION OF SEXUAL SIDE-EFFECTS [J].
DEGASPARO, M ;
WHITEBREAD, SE ;
PREISWERK, G ;
JEUNEMAITRE, X ;
CORVOL, P ;
MENARD, J .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1989, 32 (1B) :223-227
[6]   Optimisation of antihypertensive treatment by crossover rotation of four major classes [J].
Dickerson, JEC ;
Hingorani, AD ;
Ashby, MJ ;
Palmer, CR ;
Brown, MJ .
LANCET, 1999, 353 (9169) :2008-2013
[7]  
Duncan Karl, 2001, American Journal of Hypertension, V14, p196A, DOI 10.1016/S0895-7061(01)01707-1
[8]  
Flack J M, 1999, J Hypertens Suppl, V17, pS19
[9]   Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals [J].
Gerstein, HC ;
Mann, JFE ;
Yi, QL ;
Zinman, B ;
Dinneen, SF ;
Hoogwerf, B ;
Hallé, JP ;
Young, J ;
Rashkow, A ;
Joyce, C ;
Nawaz, S ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (04) :421-426
[10]   Hypertension-related morbidity and mortality in the southeastern United States [J].
Hall, WD ;
Ferrario, CM ;
Moore, MA ;
Hall, JE ;
Flack, JM ;
Cooper, W ;
Simmons, JD ;
Egan, BM ;
Lackland, DT ;
Perry, M ;
Roccella, EJ .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 313 (04) :195-209